AIM: In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury. Knowledge about the consequences of bevacizumab on chemotherapy-induced hepatic injury and tumor response is limited. METHODS: Resected liver specimens from patients of two prospective, non-randomized trials (5-fluorouracil/oxaliplatin+/-bevacizumab) were analyzed retrospectively. Hepatotoxicity to the non-tumor bearing liver was evaluated for sinusoidal obstruction syndrome, hepatic steatosis and fibrosis. Tumor response under chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS: Bevacizumab decreased the severity of the sinusoidal obstruction syndrome. Bevacizumab had no impact on hepatic steatosis and fibrosis. The addition of bevacizumab to chemotherapy had no effect on tumor response compared to combination chemotherapy alone. CONCLUSIONS: This analysis shows that bevacizumab protects against the sinusoidal obstruction syndrome and thus provides the histological explanation of the safe use of bevacizumab prior to liver resection. Furthermore, we show that bevacizumab does not improve tumor response according to RECIST.
AIM: In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury. Knowledge about the consequences of bevacizumab on chemotherapy-induced hepatic injury and tumor response is limited. METHODS: Resected liver specimens from patients of two prospective, non-randomized trials (5-fluorouracil/oxaliplatin+/-bevacizumab) were analyzed retrospectively. Hepatotoxicity to the non-tumor bearing liver was evaluated for sinusoidal obstruction syndrome, hepatic steatosis and fibrosis. Tumor response under chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST). RESULTS:Bevacizumab decreased the severity of the sinusoidal obstruction syndrome. Bevacizumab had no impact on hepatic steatosis and fibrosis. The addition of bevacizumab to chemotherapy had no effect on tumor response compared to combination chemotherapy alone. CONCLUSIONS: This analysis shows that bevacizumab protects against the sinusoidal obstruction syndrome and thus provides the histological explanation of the safe use of bevacizumab prior to liver resection. Furthermore, we show that bevacizumab does not improve tumor response according to RECIST.
Authors: M L Gómez Dorronsoro; R Vera; L Ortega; C Plaza; R Miquel; M García; E Díaz; M R Ortiz; J Pérez; C Hörndler; C Villar; J Antúnez; S Pereira; F López-Rios; R González-Cámpora Journal: Clin Transl Oncol Date: 2013-09-10 Impact factor: 3.405
Authors: R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras Journal: Clin Transl Oncol Date: 2013-12-12 Impact factor: 3.405
Authors: Roderich E Schwarz; Jordan D Berlin; Heinz J Lenz; Bernard Nordlinger; Laura Rubbia-Brandt; Michael A Choti Journal: HPB (Oxford) Date: 2012-09-24 Impact factor: 3.647
Authors: Nicolas Golse; Petru O Bucur; René Adam; Denis Castaing; Antonio Sa Cunha; Eric Vibert Journal: J Gastrointest Surg Date: 2012-11-18 Impact factor: 3.452
Authors: K Dede; T Mersich; I Besznyák; A Zaránd; F Salamon; Z S Baranyai; L Landherr; F Jakab; A Bursics Journal: Pathol Oncol Res Date: 2013-02-19 Impact factor: 3.201